Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Addiction Therapeutics Reviewed by NeuroInvestment
Nov 14, 2008 10:44 AM
- New Progress on Treatment to Keep You Safe Following Surgery
Nov 13, 2008 12:12 PM
- Cortex Reports Third Quarter Operating Results
Nov 07, 2008 08:33 AM
- Cortex's CEO to Present at Rodman & Renshaw's Tenth Annual Healthcare Conference on November 10, 2008
Nov 06, 2008 02:22 PM
- Cortex's AMPAKINE(R) Research in Opioid-induced Respiratory Depression Makes Windhover's Top 10 List of Neuroscience Projects Available for Partnering
Oct 09, 2008 01:48 PM
- Cortex's AMPAKINE Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany
Oct 06, 2008 08:50 AM
- Alzheimer's Therapeutics Reviewed by NeuroInvestment
Sep 02, 2008 11:47 AM
- Cortex Reports Second Quarter Operating Results
Aug 11, 2008 08:49 AM
- Cortex's AMPAKINE Molecule CX717 Has Positive Effects in Opiate-Induced Respiratory Depression in a Phase IIa Clinical Study
Aug 06, 2008 08:40 AM
- *Revised* Analyst Reports for Cortex Pharmaceuticals Inc., Seabridge Gold Inc., Anooraq Resources Corporation, and Cano Petroleum Inc.
Jul 31, 2008 01:13 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
COR
|
Compare to S&P
|
| YTD |
39.39 %
|
128.38 %
|
| 4 Weeks |
-4.18 %
|
3.57 %
|
| 12 Weeks |
-25.81 %
|
2.84 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 12.50 %
|
|
EPS Growth in Last Year: 0.00 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
|
